摘要
目的观察美罗华联合DICE方案治疗国人复发和难治性侵袭性B细胞非霍奇金淋巴瘤的疗效及不良反应。方法全组共15例采用美罗华375mg/m2,于化疗第1个周期前1天开始,每周输注1次,连续4次。化疗采用DICE方案,化疗每3周循环一个周期,3个周期后评价疗效及不良反应。结果15例患者中,有14例可以评价客观疗效,其中获得CR7例(50.0%),PR4例(28.6%),总有效率78.5%,1年无进展生存(PFS)率为50.1%,1年总生存(OS)率为64.3%。不良反应均可耐受,主要为输注相关的不良反应和化疗相关的血液学毒副反应。结论经过初步应用,可以得出美罗华联合DICE方案是治疗国人复发和难治性侵袭性B细胞淋巴瘤的有效方案,完全缓解率高且毒性反应可以耐受。
Objective：To evaluate the efficacy and toxicity of rituximab plus DICE regimen in relapsed or refractory patients with aggressive B-cell lymphoma. Methods：IS patients were enrolled in this study. Rituximab was given at the dose of 375mg/m^2 every 1 week for 4 times and the first day that rituximab was administered was the day-1 before the initiation of the first chemotherapy course. Chemotherapy was conducted with DICE regimen every 3 weeks for 3 courses. Results：There were 14 of the 15 patients might be evalu- ated for the objective efficiency. The total response rate was 78. 6% , the complete remission was observed in 7 patients（ 50. 0% ） and partial remission was observed in 4 patients （28. 6% ）. The 1-year progression-free and overall survial rates were 50. 1% and 64. 3% , respectively. The therapy could be well tolerated, and the major side effects were infusion related response and hematological toxicities. Conclusion：DICE regimen plus rituximab is an effective salvage therapy for the patients with relapsed refractory aggressive B-cell lymphoma. The complete remission rate is high and the toxicities can be tolerated.
出处
《临床肿瘤学杂志》
CAS
2006年第3期210-212,共3页
Chinese Clinical Oncology
